{"title":"Myasthenia Gravis","authors":"M. Hawkes, E. Wijdicks","doi":"10.1093/med/9780190862923.003.0093","DOIUrl":null,"url":null,"abstract":"Myasthenia gravis (MG) is a well-characterized B-cell–mediated disease caused by autoantibodies against targets located in the postsynaptic end plate of the neuromuscular junction. Fluctuating weakness and fatigability are clinical hallmarks of this disease. MG can be divided into subgroups based on the age at onset, serum antibodies, and thymic tumor, and different clinical courses can be anticipated with each. This chapter describes general concepts about MG, focusing on the triage, work-up, and management of severe myasthenic exacerbation (crisis).","PeriodicalId":308040,"journal":{"name":"Mayo Clinic Critical and Neurocritical Care Board Review","volume":"78 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mayo Clinic Critical and Neurocritical Care Board Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/med/9780190862923.003.0093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Myasthenia gravis (MG) is a well-characterized B-cell–mediated disease caused by autoantibodies against targets located in the postsynaptic end plate of the neuromuscular junction. Fluctuating weakness and fatigability are clinical hallmarks of this disease. MG can be divided into subgroups based on the age at onset, serum antibodies, and thymic tumor, and different clinical courses can be anticipated with each. This chapter describes general concepts about MG, focusing on the triage, work-up, and management of severe myasthenic exacerbation (crisis).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
